Test drug that targets CD73, alone or with immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer with a measurable spot on scans (that can be tracked over time).
- Your cancer type and prior treatment fit one of the study groups (including certain NSCLC or pancreatic cancer situations).
- You can provide a tumor tissue sample (from an old biopsy or a new one) so researchers can test CD73 and PD-L1, unless the study doctor says it’s too risky.
- Your body is strong enough for treatment, with an ECOG score of 0 or 1 (meaning you’re able to do most daily activities).
- You’re not currently pregnant or breastfeeding, and if you could become pregnant, you can use reliable birth control.
- You don’t have certain health conditions that could make immune treatment unsafe (like recent serious immune lung or heart inflammation, or active autoimmune disease needing medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
This trial tests a new drug combined with chemotherapy compared to a standard immunotherapy combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the new combination is more effective and may offer a new first-line treatment option.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.